Abstract
Nicotine addiction is a complex behavioural alteration, in which many neuronal pathways and neurotransmitters are involved. For a long time, dopamine has been considered one of the most important neurotransmitters in mediating the rewarding effects of nicotine. In addition, a great amount of research suggests that the endogenous cannabinoid and opioid systems play an overall modulatory effect on the reward circuitry and participate in the addictive properties of most of the prototypical drugs of abuse. This review focuses on recent behavioural and biochemical data involving these systems in the different processes that contribute to tobacco addiction. A possible role for the endogenous cannabinoid and opioid systems in the rewarding properties of nicotine as well as in the development of nicotine physical dependence and relapse to nicotine-seeking behaviour will be examined. According to preclinical studies, clinical trials suggest that the manipulation of these systems with cannabinoid or opioid antagonists could be a potential therapeutical strategy for treating nicotine addiction.
Keywords: Nicotine, addiction, cannabinoid, opioid, reward, withdrawal syndrome, relapse, self-administration
Current Drug Targets
Title: Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction
Volume: 11 Issue: 4
Author(s): Rafael Maldonado and Fernando Berrendero
Affiliation:
Keywords: Nicotine, addiction, cannabinoid, opioid, reward, withdrawal syndrome, relapse, self-administration
Abstract: Nicotine addiction is a complex behavioural alteration, in which many neuronal pathways and neurotransmitters are involved. For a long time, dopamine has been considered one of the most important neurotransmitters in mediating the rewarding effects of nicotine. In addition, a great amount of research suggests that the endogenous cannabinoid and opioid systems play an overall modulatory effect on the reward circuitry and participate in the addictive properties of most of the prototypical drugs of abuse. This review focuses on recent behavioural and biochemical data involving these systems in the different processes that contribute to tobacco addiction. A possible role for the endogenous cannabinoid and opioid systems in the rewarding properties of nicotine as well as in the development of nicotine physical dependence and relapse to nicotine-seeking behaviour will be examined. According to preclinical studies, clinical trials suggest that the manipulation of these systems with cannabinoid or opioid antagonists could be a potential therapeutical strategy for treating nicotine addiction.
Export Options
About this article
Cite this article as:
Maldonado Rafael and Berrendero Fernando, Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction, Current Drug Targets 2010; 11 (4) . https://dx.doi.org/10.2174/138945010790980358
DOI https://dx.doi.org/10.2174/138945010790980358 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology Neurotoxicity of Insecticides
Current Medicinal Chemistry Brain Connectivity and Gyrification as Endophenotypes for Schizophrenia: Weight of the Evidence
Current Topics in Medicinal Chemistry Alpha7 Neuronal Nicotinic Receptors as Targets for Novel Therapies to Treat Multiple Domains of Schizophrenia
Current Pharmaceutical Biotechnology Effects of Exercise on Physical and Mental Health, and Cognitive and Brain Functions in Schizophrenia: Clinical and Experimental Evidence
CNS & Neurological Disorders - Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research Modulation of the Intrinsic Properties of Motoneurons by Serotonin
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Current Pharmaceutical Design The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Harnessing Anesthesia and Brain Imaging for the Study of Human Consciousness
Current Pharmaceutical Design Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets The Behavioral Control of Breathing: Sensory and Motor Aspects
Current Respiratory Medicine Reviews Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research